Kezar Life Sciences, Inc. (KZR)
Automate Your Wheel Strategy on KZR
With Tiblio's Option Bot, you can configure your own wheel strategy including KZR - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol KZR
- Rev/Share 0.1426
- Book/Share 14.1081
- PB 0.2963
- Debt/Equity 0.0993
- CurrentRatio 7.093
- ROIC -0.7193
- MktCap 30538244.0
- FreeCF/Share -9.3868
- PFCF -0.4453
- PE -0.3884
- Debt/Assets 0.0817
- DivYield 0
- ROE -0.6232
- Rating B-
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 5
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Kezar Life Sciences (KZR) Upgraded to Buy: What Does It Mean for the Stock?
Published: May 27, 2025 by: Zacks Investment Research
Sentiment: Positive
Kezar Life Sciences (KZR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Read More
Kezar Life Sciences Announces Positive Topline Results from the PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis (AIH) and Reports Fourth Quarter and Year End 2024 Financial Results
Published: March 25, 2025 by: Business Wire
Sentiment: Neutral
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today reported positive topline results from the PORTOLA Phase 2a clinical trial evaluating zetomipzomib, a novel, first-in-class selective immunoproteasome inhibitor, in patients with autoimmune hepatitis (AIH) and reported fourth quarter and year end 2024 financial results. “.
Read More
Kezar Life Sciences to Present Topline Results from the PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis on March 25, 2025
Published: March 24, 2025 by: Business Wire
Sentiment: Neutral
SOUTH SAN FRANCISCO, CALIF.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced that it will present topline results from the PORTOLA Phase 2a trial evaluating zetomipzomib for the treatment of patients with autoimmune hepatitis (AIH) on Tuesday, March 25, 2025, at 8:00 a.m. ET. The event will highlight topline data from Kezar's PORTOLA tri.
Read More
About Kezar Life Sciences, Inc. (KZR)
- IPO Date 2018-06-21
- Website https://www.kezarlifesciences.com
- Industry Biotechnology
- CEO Dr. Christopher J. Kirk Ph.D.
- Employees 55